Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BeiGene (BGNE)
NASDAQ:BGNE
Holding BGNE?
Track your performance easily
BGNE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$126.97 - $248.16
Previous Close$176.5
Volume368.47K
Average Volume (3M)387.78K
Market Cap
$19.81B
Enterprise Value$24.54B
Total Cash (Recent Filing)$2.70B
Total Debt (Recent Filing)$7.43B
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Mar 26, 2025EPS Estimate
-$0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.24
Shares Outstanding106,618,025
10 Day Avg. Volume481,485
30 Day Avg. Volume387,782
Standard Deviation0.13
R-Squared0.05
Alpha0.00237
Financial Highlights & Ratios
Price to Book (P/B)5.48
Price to Sales (P/S)1.93
Price to Cash Flow (P/CF)24.70
P/FCF Ratio64.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.40
Enterprise Value/Gross Profit11.80
Enterprise Value/Ebitda-32.78
Forecast
1Y Price Target
$257.90Price Target Upside46.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
BeiGene News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyBrukinsa demonstrated well-tolerated results in patients previously intolerant to other treatments, with high disease control rates.
Market PositionBGNE's CLL trials cover the entire treatment landscape, positioning the company well to capture the full value of the CLL market.
Pipeline DevelopmentThe pivotal Phase 3 of Sonrotoclax (BCL-2 inhibitor) plus Brukinsa is progressing rapidly with enrollment nearly completed, indicating strong potential for future success.
Bears Say
Growth RateThe ~8% QoQ growth rate is lower than prior quarters, where QoQ growth has been typically in the mid-to-high teens.
Market CompetitionDespite progress, competition in the domestic market remains a balancing factor for the company's performance.
Operational PerformanceThe company's loss from operations was reduced to US$120.3 million from US$134.0 million.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BGNE FAQ
What was BeiGene’s price range in the past 12 months?
BeiGene lowest stock price was $126.97 and its highest was $248.16 in the past 12 months.
What is BeiGene’s market cap?
Currently, no data Available
When is BeiGene’s upcoming earnings report date?
BeiGene’s upcoming earnings report date is Mar 26, 2025 which is in 95 days.
How were BeiGene’s earnings last quarter?
BeiGene released its earnings results on Nov 12, 2024. The company reported -$1.15 earnings per share for the quarter, missing the consensus estimate of -$1.114 by -$0.036.
Is BeiGene overvalued?
According to Wall Street analysts BeiGene’s price is currently Undervalued.
Does BeiGene pay dividends?
BeiGene does not currently pay dividends.
What is BeiGene’s EPS estimate?
BeiGene’s EPS estimate is -$0.92.
How many shares outstanding does BeiGene have?
BeiGene has 97,617,820 shares outstanding.
What happened to BeiGene’s price movement after its last earnings report?
BeiGene reported an EPS of -$1.15 in its last earnings report, missing expectations of -$1.114. Following the earnings report the stock price went down -5.56%.
Which hedge fund is a major shareholder of BeiGene?
Among the largest hedge funds holding BeiGene’s share is Baker Bros Advisors LP. It holds BeiGene’s shares valued at 2B.
---
BeiGene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$257.90 (46.12% Upside)
$257.90 (46.12% Upside)
Blogger Sentiment
Bullish
BGNE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 48.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.8B over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.71%
12-Months-Change
Fundamentals
Return on Equity
-23.90%
Trailing 12-Months
Asset Growth
5.54%
Trailing 12-Months
Company Description
BeiGene
BeiGene, Ltd.is a biopharmaceutical company. The company primarily focuses on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer.
---
BGNE Stock 12 Month Forecast
Average Price Target
$257.90
▲(46.12% Upside)
Technical Analysis
Best Analysts Covering BGNE
1 Year
1 Year Success Rate
20/28 ratings generated profit
1 Year Average Return
+26.59%
reiterated a buy rating 5 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +26.59% per trade.
---